The Market Reports

Synopsis
The global market for Human Coagulation Factor VIII was estimated to be worth US$ 11550 million in 2024 and is forecast to a readjusted size of US$ 17610 million by 2031 with a CAGR of 6.3% during the forecast period 2025-2031.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
Market Drivers:
The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.
Market Challenges:
Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.
This report aims to provide a comprehensive presentation of the global market for Human Coagulation Factor VIII, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Coagulation Factor VIII by region & country, by Type, and by Application.
The Human Coagulation Factor VIII market size, estimations, and forecasts are provided in terms of sales volume (K Bottles) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Coagulation Factor VIII.
Market Segmentation
By Company
Takeda
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
SinoCellTech
Taibang Bio
Huarun Boya
Shuanglin Bio
Yuandashuyang
Weiguang Bio
Segment by Type
Recombinant Factor VIII
Plasma-derived Factor VIII
Segment by Application
Hemophilia A
Spontanous / Trauma
Surgical
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Human Coagulation Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Human Coagulation Factor VIII in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index